Author | David A. Mrazek, MD


Pharmacogenomic Screening for Depressed Children and Adolescents

August 01, 2005

While the utilization of clinical genotyping to determine drug response and dosage has been anticipated for many years, the actual utilization of screening for atypical drug metabolizers has only recently become a reality. What is the promise of this technology, as well as the limitations?